Cite
HARVARD Citation
Bendell, J. et al. (2017). A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist. pp. 264-271. [Online].